A Phase 2, Open Label Study of the Safety and Effectiveness of MDMA-assisted Therapy for Participants With Posttraumatic Stress Disorder
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Acronyms NUMCAP1
- Sponsors Lykos Therapeutics
- 27 Jan 2022 Planned End Date changed from 1 Feb 2023 to 1 Aug 2023.
- 27 Jan 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2023.
- 27 Jan 2022 Planned initiation date changed from 1 May 2022 to 1 Aug 2022.